EDITORIAL
852 The N-MOmentum trial: Building momentum to advance trial methodology in a rare disease
J Chataway and T Friede

TOPICAL REVIEW
855 Urinary tract infections in multiple sclerosis
V Phé, M Pakzad, C Curtis, et al.

FUTURE PERSPECTIVES
862 Placebo-controlled study in neuromyelitis optica—Ethical and design considerations
BAC Cree, JL Bennett, M Sheehan, et al.

CONTROVERSIES IN MULTIPLE SCLEROSIS
873 All relapsing multiple sclerosis patients should be managed at a specialist clinic – YES
WJ Brownlee and O Ciccarelli
875 All relapsing multiple sclerosis patients should be seen in specialist clinics – NO
R Brenner
876 All relapsing multiple sclerosis patients should be managed at a specialist clinic – Commentary
M Hutchinson

ORIGINAL RESEARCH PAPERS
878 Body mass index during adolescence, rather than childhood, is critical in determining MS risk
AK Hedström, T Olsson and L Alfredsson
884 Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: Results from the Ausimmune Study
S Hoare, F Lithander, I van der Mei, A-L Ponsonby and R Lucas for the Ausimmune Investigator Group
893 Optical coherence tomography indicates disease activity prior to clinical onset of central nervous system demyelination
B Knier, A Berthele, D Buck, et al.
901 Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study
JM Tillema, HE Hulst, MA Rocca, et al.
910 Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis
H Kearney, KA Miszkiel, MC Yiannakas, et al.
921 Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis
E Signoriello, R Lanzillo, V Brescia Morra, et al.
926 Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis
R Ratzer, P Iversen, L Børnsen, et al.
935 Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort
944 Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine
R Macdonell, G Nagels, D-A Laplaud, et al.

SHORT REPORTS
955 Efficacy of rituximab in refractory neuromyelitis optica
N Collongues, D Brassat, E Maillart, et al.
960 Spinal cord involvement in Behçet’s disease
HS Lee, DY Kim, HY Shin, Y-C Choi and SM Kim
964 The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients
S Siritho, DK Sato, K Kaneko, K Fujihara and N Prayoonwiwat

CASE REPORTS
969 Extensive molluscum contagiosum virus infection in a young adult receiving fingolimod
V Behle, M Wobser, M Goebeler and J Stoevesandt
972 Susac’s syndrome: Leptomeningeal enhancement on 3D FLAIR MRI
R Engisch, DS Titelbaum, L Chilver-Stainer and F Kellner-Weldon

CLINICAL COMMENTARY
975 Leptomeningeal enhancement in Susac’s syndrome and multiple sclerosis: Time to expect the unexpected?
J Sastre-Garriga

Cover image adapted from Figure 4, in the article, Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study, by JM Tillema, HE Hulst, MA Rocca, H Vrenken, MD Steenwijk, D Damjanovic, C Eazinger, S Ropele, G Tedeschi, A Gallo, O Ciccarelli, A Rovira, X Montalban, N de Stefano, ML Stromillo, M Filippi, and F Barkhof on behalf of the MAGNIMS Study Group, page 906.